Abstract
Late last year when President Biden signed the “omnibus” spending bill eliminating the X‐waiver and the patient caps for buprenorphine, prescribers were thrilled. The American Society of Addiction Medicine (ASAM), which had fought hard for the changes, claimed that the X‐waiver, formerly required by the Drug Enforcement Administration (DEA), was a barrier to prescribing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Brown University Child and Adolescent Behavior Letter
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
